Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
immunotherapy
gene therapy engineered T cell |
| gptkbp:administeredBy |
infusion
|
| gptkbp:antigen |
gptkb:TCR_complex
antibody-based binding domain |
| gptkbp:benefit |
broader tumor recognition
improved safety profile reduced cytokine release syndrome |
| gptkbp:category |
cellular immunotherapy
genetically engineered cell |
| gptkbp:clinicalTrialPhase |
Phase 1/2
NCT03907852 |
| gptkbp:contrastsWith |
CAR-T cells
|
| gptkbp:deliveredBy |
intravenous infusion
|
| gptkbp:developedBy |
gptkb:TCR2_Therapeutics
|
| gptkbp:distinctFrom |
do not require HLA matching
engage full TCR signaling complex |
| gptkbp:expressedIn |
TCR fusion construct
|
| gptkbp:fabricationProcess |
quality control
cell expansion ex vivo genetic modification |
| gptkbp:firstClinicalTrial |
Gavo-cel (TC-210)
|
| gptkbp:firstReported |
2018
|
| gptkbp:firstTargetAntigen |
mesothelin
|
| gptkbp:fullName |
T cell Receptor Fusion Construct T cells
|
| https://www.w3.org/2000/01/rdf-schema#label |
TRuC-T cells
|
| gptkbp:mechanismOfAction |
fuse antibody-based binding domain to TCR complex
redirect T cells to recognize tumor antigens |
| gptkbp:patent |
gptkb:TCR2_Therapeutics
|
| gptkbp:preclinicalModel |
mouse xenograft
|
| gptkbp:preclinicalResult |
tumor regression
prolonged survival |
| gptkbp:regulates |
investigational
|
| gptkbp:relatedTo |
CAR-T cells
TCR-T cells |
| gptkbp:sideEffect |
gptkb:anemia
fatigue neutropenia cytokine release syndrome |
| gptkbp:sourceCellType |
autologous T cells
allogeneic T cells |
| gptkbp:target |
gptkb:cancer
mesothelioma cholangiocarcinoma solid tumors gastric cancer hematologic malignancies |
| gptkbp:treatment |
personalized medicine
adoptive cell therapy |
| gptkbp:usedFor |
gptkb:cancer
|
| gptkbp:bfsParent |
gptkb:TCR2_Therapeutics
|
| gptkbp:bfsLayer |
8
|